Progress regarding improved outcomes for asthma patients globally has slowed significantly in the last decade, due in part to the prevalence of treating it as a homogenous disease (Custovic et al, 2019, p.26). The problem lies in the clinical approach; endotyping asthma is currently dichotomised between type 2 (eosinophilic) response and non-type 2 (neutrophilic) response, which has proven to be a simplified categorisation that fails to reflect the complexity of the pathological process (Jeong et al., 2019, p.3). A better understanding of the mechanisms of asthma pathogenesis is particularly important for patients currently categorised as non-type 2 for whom there is no effective therapeutic modality despite comprising approximately 50% of all asthma patients (Jeong et al., 2019, p.10). The standard comprehensive management of asthma depends on a stepwise approach and comprises inhaled corticosteroids (ICSs), B2 -agonists and leukotriene receptor antagonists (LRTAs) for symptom control (Eyerich et al., 2019, p.547). Recent developments in the research of asthma focusing on its heterogeneity and classification of its specific endotypes have led to new approaches, such as stratified medicine, and novel treatments based on biologicals. It is accepted that humanized monoclonal antibody (mAb) treatments are safe in adult patients with moderate-to-severe asthma (Varricchi et al., 2019(Varricchi et al., , p. 2801. Many mAb treatments have been approved after favourable trials; existing medications with a good safety profile include omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab, which have been shown to reduce exacerbations in patients (adult and pediatric) with severe persistent uncontrolled asthma (Delimpoura et al., 2018; Eyerich et al., 2019). Thymic stromal lymphopoietin (TSLP) has been associated with asthma pathophysiology; tezepelumab is a promising new mAb that specifically targets TSLP (Marone et al., 2019, p.1). A phase 2, randomized, double-blind, placebo-controlled trial carried out by Corren and co-authors (2017, p.936) compared exacerbation events per patient-year in patients who were given three dose levels with placebo over a 52-week treatment period. The trial showed favourable outcomes; exacerbation rates in the tezepelumab groups were lower by 62%, 71%, and 66% than the rate in the placebo group, providing clinical evidence